This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Sun Yat-Sen University Cancer Center, Sun Yat-Senuniversity. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 6 
1 out of 116 
Years Active: 2026
Title: Tong Xiang: Advancing Combination Therapy Research for Liver Cancer.
Introduction.
Tong Xiang is an inventor associated with Guangzhou, China. His patent work focuses on a proposed combination approach for treating hepatocellular carcinoma, a common form of liver cancer.
Latest Patents.
Xiang is named on 1 patent: “Use of BMP9 in Combination with NK Cell and PD-L1 Antibody in Preparing Medicament for Treating Liver Cancer.” The invention describes loading BMP9 onto drug-carrier microbubbles to create BMP9-carrying microbubbles, then using them alongside natural killer (NK) cells and a programmed death-ligand 1 (PD-L1) antibody. The patent presents this combination as a way to enhance the effects of PD-L1 antibody therapy and inhibit the growth of hepatocellular carcinoma cell-graft tumors.
Career Highlights.
The provided information associates Xiang with Sun Yat-Sen University and Sun Yat-Sen University Cancer Center. His patent reflects research into combining a therapeutic molecule, immune cells, and checkpoint-blocking antibodies in an approach to cancer treatment.
Collaborations.
Jianchuan Xia and Yulong Han are identified as Xiang’s coworkers. Their names are associated with the collaborative research context surrounding his patent work.
Conclusion.
Tong Xiang’s documented invention explores a combination of BMP9-carrying microbubbles, NK cells, and a PD-L1 antibody as a potential strategy for treating liver cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile